Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2022
|
Karen M Dahut Director |
BUY
Bona fide gift
|
Indirect |
1,548
+18.61%
|
-
|
|
Aug 11
2022
|
Karen M Dahut Director |
SELL
Bona fide gift
|
Direct |
1,548
-21.99%
|
-
|
|
Jul 25
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,000
-0.72%
|
$83,000
$83.07 P/Share
|
|
Jun 23
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,000
-0.71%
|
$72,000
$72.55 P/Share
|
|
Jun 06
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-3.33%
|
$180,600
$301.57 P/Share
|
|
May 24
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.71%
|
$74,000
$296.33 P/Share
|
|
May 20
2022
|
Steven R Altman Director |
BUY
Grant, award, or other acquisition
|
Direct |
979
+50.0%
|
-
|
|
May 20
2022
|
Nicholas Augustinos Director |
BUY
Grant, award, or other acquisition
|
Direct |
994
+50.0%
|
-
|
|
May 20
2022
|
Richard Alexander Collins Director |
BUY
Grant, award, or other acquisition
|
Direct |
987
+50.0%
|
-
|
|
May 20
2022
|
Karen M Dahut Director |
BUY
Grant, award, or other acquisition
|
Direct |
987
+35.93%
|
-
|
|
May 20
2022
|
Mark G Foletta Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,122
+50.0%
|
-
|
|
May 20
2022
|
Bridgette P Heller Director |
BUY
Grant, award, or other acquisition
|
Direct |
988
+15.58%
|
-
|
|
May 20
2022
|
Barbara Kahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
994
+50.0%
|
-
|
|
May 20
2022
|
Kyle Malady Director |
BUY
Grant, award, or other acquisition
|
Direct |
979
+23.65%
|
-
|
|
May 20
2022
|
Jay S Skyler Director |
BUY
Grant, award, or other acquisition
|
Direct |
969
+50.0%
|
-
|
|
May 20
2022
|
Eric Topol Director |
BUY
Grant, award, or other acquisition
|
Direct |
988
+50.0%
|
-
|
|
May 19
2022
|
Steven R Altman Director |
BUY
Other acquisition or disposition
|
Indirect |
910
+5.83%
|
-
|
|
May 19
2022
|
Steven R Altman Director |
SELL
Other acquisition or disposition
|
Direct |
910
-100.0%
|
-
|
|
May 19
2022
|
Nicholas Augustinos Director |
BUY
Other acquisition or disposition
|
Indirect |
918
+9.74%
|
-
|
|
May 19
2022
|
Nicholas Augustinos Director |
SELL
Other acquisition or disposition
|
Direct |
918
-100.0%
|
-
|
|
May 19
2022
|
Richard Alexander Collins Director |
BUY
Other acquisition or disposition
|
Indirect |
910
+10.08%
|
-
|
|
May 19
2022
|
Richard Alexander Collins Director |
SELL
Other acquisition or disposition
|
Direct |
910
-100.0%
|
-
|
|
May 19
2022
|
Karen M Dahut Director |
BUY
Other acquisition or disposition
|
Indirect |
918
+41.3%
|
-
|
|
May 19
2022
|
Karen M Dahut Director |
SELL
Other acquisition or disposition
|
Direct |
918
-54.29%
|
-
|
|
May 19
2022
|
Mark G Foletta Director |
BUY
Other acquisition or disposition
|
Indirect |
1,054
+7.17%
|
-
|
|
May 19
2022
|
Mark G Foletta Director |
SELL
Other acquisition or disposition
|
Direct |
1,054
-100.0%
|
-
|
|
May 19
2022
|
Barbara Kahn Director |
BUY
Other acquisition or disposition
|
Indirect |
918
+18.98%
|
-
|
|
May 19
2022
|
Barbara Kahn Director |
SELL
Other acquisition or disposition
|
Direct |
918
-100.0%
|
-
|
|
May 19
2022
|
Jay S Skyler Director |
BUY
Other acquisition or disposition
|
Indirect |
900
+5.71%
|
-
|
|
May 19
2022
|
Jay S Skyler Director |
SELL
Other acquisition or disposition
|
Direct |
900
-100.0%
|
-
|
|
May 19
2022
|
Eric Topol Director |
BUY
Other acquisition or disposition
|
Indirect |
919
+0.98%
|
-
|
|
May 19
2022
|
Eric Topol Director |
SELL
Other acquisition or disposition
|
Direct |
919
-100.0%
|
-
|
|
May 09
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
777
-5.38%
|
$265,734
$342.77 P/Share
|
|
Apr 25
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.7%
|
$109,750
$439.94 P/Share
|
|
Apr 11
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
776
-5.1%
|
$386,448
$498.75 P/Share
|
|
Mar 29
2022
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
1,106
-6.34%
|
$553,000
$500.0 P/Share
|
|
Mar 23
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.7%
|
$114,750
$459.98 P/Share
|
|
Mar 17
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
484
-6.8%
|
$217,800
$450.0 P/Share
|
|
Mar 16
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
686
-8.79%
|
$291,550
$425.0 P/Share
|
|
Mar 15
2022
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,000
-0.3%
|
$1,230,000
$410.78 P/Share
|
|
Mar 15
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
1,016
-11.52%
|
$418,592
$412.41 P/Share
|
|
Mar 10
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,366
-17.12%
|
$948,766
$401.27 P/Share
|
|
Mar 10
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
776
-4.85%
|
$311,176
$401.27 P/Share
|
|
Mar 09
2022
|
Donald Abbey EVP Global Business Services I |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.18%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,430
-6.39%
|
$1,392,580
$406.06 P/Share
|
|
Mar 09
2022
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,615
-4.11%
|
$655,690
$406.06 P/Share
|
|
Mar 09
2022
|
Paul R Flynn EVP Global Revenue |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,967
-5.45%
|
$1,204,602
$406.06 P/Share
|
|
Mar 09
2022
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,273
-1.83%
|
$1,734,838
$406.06 P/Share
|
|
Mar 09
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.99%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Chad Patterson EVP Global Marketing |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,821
-2.64%
|
$739,326
$406.06 P/Share
|